Pyc Therapeutics Ltd has released a press release.
PYC-001 Effective In Both NHPs and Patient-Derived Models
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from PYC Therapeutics
- Safety Review Committee Approves Dose Escalation
- RP11 Clinical Trial Dosing Completed In Patient Cohort 1
- PYC Increases Ownership of VP-001 Program
- PYC Receives FDA Fast Track Designation
- Successful Toxicology Results Pave Way for Phase 2 Trial
Later from PYC Therapeutics
- RP11 Clinical Trial Dosing Completed In Patient Cohort 2
- PYC and FDA Align On Clinical Trial Pathway in ADOA
- New Drug For Major Kidney Disease Effective In Human Models
- Supplementary Information
- Response to Price Query
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics